Abstract:OBJECTIVES:To evaluate the clinical significance of flow cytometry (FCM) to detect the cytomegalovirus (CMV) PP65 antigen in patients with CMV infection. METHODS:Samples from 35 patients without CMV infection were used as negative control. The definite diagnosis of CMV infection was based on the national criteria for CMV infection. All 136 patients with CMV infection were examined with the FCM to detect CMV PP65 antigen, real-time fluorescence quantitative-polymerase chain reaction assay (RFQ-PCR) to detect CMV-DNA and ELISA to measure the serum level of IgM antibody against CMV. The results of these 3 assays in 2 groups (isolated organ involvement and disseminated diseases) were compared and the significance of PP65 antigenemia was evaluated. A short-term follow-up was undertaken in 18 patients. RESULTS:The percentages of PP65 positivity in blood mononuclear cells (MNC) and polymorphic nuclear leukocyte (PMNL) from 35 negative control patients were 0.21% +/- 0.09% with a range of 0 - 0.41% and 0.24% +/- 0.10% with a range of 0.12% - 0.48%, respectively, which were not significantly different (t = 0.425, P > 0.05). The 95(th) percentiles (P(95)) of PP65 in MNC and PMNL were 0.39% and 0.45%, respectively, so a cutoff value of >/= 0.50% was set. Of the 136 patients with CMV infection, 118 samples from 118 patients were positive for PP65 antigenemia with a positive rate of 86.8%, which was not statistically different from that (90.4%, chi(2) = 0.91, P > 0.05) of CMV-DNA detected by RFQ-PCR assay but it was significantly higher than that (45.6%, chi(2) = 51.50, P < 0.005) of the detection by IgM measurement. PP65 detection was correlated with urine CMV DNA amplification (chi(2) = 63.78, P < 0.01) while the different detection rates between the two assays were not statistically significant (chi(m)(2) = 1.78,P > 0.05). PP65 detection was not correlated with serum IgM measurement while the detection rates between the two were significantly different (chi(m)(2) = 52.92,P < 0.01). No significant difference was found between the detection rates of CMV infection in MNC (45/53, 84.9%) and PMNL (43/53, 81.1%) (chi(m)(2) = 0.25, P > 0.05). Higher PP65 antigenemia level was correlated with systemic CMV infection, while lower level of PP65 was either in the patients with isolated organ involvement by CMV (chi(2) = 38.51, P < 0.005) or less severe in patient's situation. PP65 antigenemia of CMV infection returned to lower level or negative in recovery stage and increased when condition of patients deteriorated. CONCLUSIONS:PP65 antigenemia detection by FCM is effective in the diagnosis of the active CMV infection. Quantitative monitoring of PP65 antigenemia is useful in the evaluation of patients with CMV infection.

Anti-HCMV effect of recombinant protein of HCMV pp65 and combination with Jin-Ye-Bai-Du granules

Human Cytomegalovirus Pp65 Protein Induces Specific Immune Response

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Human Mannose‐binding Lectin Inhibits Human Cytomegalovirus Infection in Human Embryonic Pulmonary Fibroblast

The clinical significance of CMV - pp65 antigen detcetion in hepatitis B virus (HBV) related hepatocellular carcinoma patients

[Application of Flow Cytometry to Detect PP65 Antigenemia for Diagnosis and Monitoring of Human Cytomegalovirus Infection].

Effect of HCMV on the Development of Human Megakaryocytes and Antiviral Effect of Antisense Oligonucleotides to HCMV

[Activity of Curcumin Against Human Cytomegalovirus Infection in Vitro].

Monitoring of human cytomegalovirus infection in bone marrow and liver transplant recipients by antigenaemia assay and enzyme-linked immunosorbent assay.

Clinical study on treatment of infantile cytomegalovirus hepatitis with integrated Chinese and Western medicine

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Efficacy of pp65‐specific TCR‐T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation

Diagnosis and treatment of human cytomegalovirus infection after liver transplantation

Inhibitory effects of piceatannol on human cytomegalovirus (hCMV) in vitro

The Complex Relationship of Cmv Igm, Pp65 Antigenemia, Plasma, and Cellular Hcmv Q-Pcr As Observed in an Immunocompetent Population and in Hsct Patients

[A Comparative Study of the Curative Effects of Cytomegalovirus Preemptive Therapy in Various Kinds of Hematopoietic Stem-Cell Transplantation].

[Surveillance of Cytomegalovirus for Antiviral Efficacy and Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation].

Curative Effect Observation of Huangqi on Assistant Treatment of Children's Cytomegalovirus

Clinical Study of Cytomegalovirus Latent Infection in Allogeneic Peripheral Blood Stem Cell Transplantation

The Study on High-Resolution HLA and Human Cytomegalovirus (HCMV) Viremia in Bone Marrow Transplantation Recipients

Adoptive Therapy with Cytomegalovirus-Specific T Cells for Cytomegalovirus Infection after Haploidentical Stem Cell Transplantation and Factors Affecting Efficacy.